Ownership
Public
Employees
~6
Stage
Phase 2
Modalities
Small molecule

Genaera General Information

Company was liquidated in 2009. Prior to liquidation, had trodusquemine (MSI-1436) in development for type 2 diabetes and obesity, and a partnered asthma program with MedImmune in Phase 2.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Plymouth Meeting, Pennsylvania
United States

Drug Pipeline

trodusquemine
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Genaera's pipeline data

Book a demo

Key Partnerships

MedImmune

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Genaera Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Genaera's complete valuation and funding history, request access »